Five phase 3 trials will collaborate internationally to answer 4 major questions in the management o...
This presentation is the property of its rightful owner.
Sponsored Links
1 / 2

Adjuvant Endometrial Cancer Trial [email protected] PowerPoint PPT Presentation


  • 139 Views
  • Uploaded on
  • Presentation posted in: General

Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer: Does proper lymphadenectomy improve survival? LYTEC Trial & AGO-ECLAT trial Is there a need for adjuvant chemotherapy in node negative high-risk early stage patients?

Download Presentation

Adjuvant Endometrial Cancer Trial [email protected]

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Adjuvant endometrial cancer trial mansoor rh regionh dk

  • Five phase 3 trials will collaborate internationally to answer 4 major questions in the management of endometrial cancer:

  • Does proper lymphadenectomy improve survival?

    • LYTEC Trial & AGO-ECLAT trial

  • Is there a need for adjuvant chemotherapy in node negative

  • high-risk early stage patients?

    • ENGOT-EN2-DGCG trial

  • Is adjuvant chemo followed by RT better than chemo alone

  • in high-risk nodal status unknown early stage or stage 3 patients?

    • NSGO trial

  • Can combination of standard chemotherapy with targeted therapy compared to combination chemotherapy alone improve disease control rate of advanced or chemo-naïve relapsed endometrial cancer?AGO/NOGGO trial

Adjuvant Endometrial Cancer Trial [email protected]


Adjuvant endometrial cancer trial mansoor rh regionh dk

ENGOT-NESTEC:NEtwork STudy in Endometrial Cancer

under the ENGOT umbrella and in cooperation with the Mayo clinic.

Clinically presumed: FIGO IB-II any histo type, FIGO I A G3 endometroid, FIGO IA/B histo type II

Mayo trial (Dowdy, Mariani)

AGO ECLAT trial (Emons)

R

R

NSGO trial (Hogberg)

surgery

R

AGO/NOGGO trial (Sehouli)

R

DGCG trial (Mirza)

No bulky LN

Bulky LN

FIGO III not Ro and pos. LN or cytology only; FIGO IV

Recurrent FIGO I/II

In OP

LNE

R

N-

N+

+ extra LN disease

R

LNE*

no LNE

without extra LN disease

N-

N+

Standard arm:

Carbo-paclitaxel

+ Placebo

Experim. arm:

Carbo-paclitaxel

+ mTOR inhibitor

R

Chemo 1

Carbo-paclitaxel

R

Chemo +.

Radiotherapy

Chemo 1

Carbo-paclitaxel

observation


  • Login